While we have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial sta

filing / Aug 14, 2026 / receipt

This potential increase will likely include increased headcount, increased stock-based compensation expenses, expanded infrastructure including certain sales and marketing activities performed ahead of regulatory approval, and increased insurance expenses.

filing / Aug 14, 2026 / receipt

We lease laboratory and office space and certain laboratory equipment under non-cancelable operating leases. The carrying value of our right-of-use lease assets is substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.

filing / Aug 14, 2026 / receipt

anticipate our general and administrative expenses would decrease in future periods as we decrease commercial manufacturing expansion projects, including at our Elkton, Maryland facility, and as we implement cost-saving initiatives, such as a reduction in compensation, a hiring freeze, and elimination of certain staff positions.

filing / Aug 14, 2026 / receipt

two five -year periods, (ii) a laboratory and manufacturing facility lease that commenced in February 2022 with a seven -year term and an option to extend for two five -year periods, and (iii) our corporate office lease that commenced in April 2020 for seven years with an option to extend for five years.

filing / Aug 14, 2026 / receipt

While we have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial sta

filing / May 14, 2026 / receipt

This potential increase will likely include increased headcount, increased stock-based compensation expenses, expanded infrastructure including certain sales and marketing activities performed ahead of regulatory approval, and increased insurance expenses.

filing / May 14, 2026 / receipt

We lease laboratory and office space and certain laboratory equipment under non-cancelable operating leases. The carrying value of our right-of-use lease assets is substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.

filing / May 14, 2026 / receipt

anticipate our general and administrative expenses would decrease in future periods as we decrease commercial manufacturing expansion projects, including at our Elkton, Maryland facility, and as we implement cost-saving initiatives, such as a reduction in compensation, a hiring freeze, and elimination of certain staff positions.

filing / May 14, 2026 / receipt

two five -year periods, (ii) a laboratory and manufacturing facility lease that commenced in February 2022 with a seven -year term and an option to extend for two five -year periods, and (iii) our corporate office lease that commenced in April 2020 for seven years with an option to extend for five years.

filing / May 14, 2026 / receipt